Johnson & Johnson and Novartis are facing patent cliffs, but both companies have strong lineups and innovative capabilities to overcome the challenges. Johnson & Johnson is experiencing a decline in sales for Stelara due to biosimilar competition, but its diversified portfolio and new products are driving growth. Novartis is preparing for generic competition for Entresto, but its extensive lineup and new products should help mitigate the impact. Both companies are also reliable dividend stocks, with Johnson & Johnson being a Dividend King and Novartis having raised its payouts for 28 consecutive years.

Read more at Nasdaq: Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm